A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japa
Phase 1
- Conditions
- Advanced Solid Tumor
- Registration Number
- JPRN-jRCT2080220419
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Ages Eligible for Study: 20 Years - 75 Years
Genders Eligible for Study: Both
Inclusion Criteria:
- advanced solid tumors
- life expectancy is 12 weeks or longer
Exclusion Criteria
- patient with uncontrolled brain metastases
- patient with inappropriate laboratory test values
- patient with poorly controlled hypertension
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety Primary Outcome Measures: - safety and tolerability Secondary Outcome Measures: - efficacy, PK
- Secondary Outcome Measures
Name Time Method